Value Of Medical Equipment Deals Declined 16% In 2012

Thursday 21 March 2013, Amsterdam

Our “Medical Equipment Annual Deals Analysis: M&A and Investments Trends - 2012” report is an essential source of data and trend analysis on mergers and acquisitions (M&A) and financing in the medical equipment market. The report provides detailed information on M&As, equity/debt offerings, private equity (PE), venture financing and partnership transactions registered in the medical equipment industry in 2012. The report includes detailed comparative data on the number of deals and their value in the past four quarters, categorized into deal types, segments, and geographies. Additionally, the report provides information on the top PE, venture capital (VC), and advisory firms in the medical equipment industry. We derived the data presented in this report from proprietary in-house Medical eTrack deals database, besides primary and secondary research.

Medical Equipment Industry Reported Decline In Deal Activity In 2012.
The medical equipment industry reported a decline in the number of deals and deal values in 2012, due to
continued economic uncertainty. The industry recorded 2,868 deals worth $119.3 billion in 2012, as compared to 2,917 deals worth $143.2 billion in 2011. The venture capital (VC) market topped the deal activity in the medical equipment industry, accounting for 34% of the total deals in 2012. Venture capital provided considerable impetus to the medical equipment industry in 2012. In-vitro diagnostics market continues to be on the top in attracting investors’ attention, as the market showed rapid growth in spite of the economic recession. The market recorded 742 deals in 2012. North America remains the favored destination for investors. The region recorded 2,209 deals in 2012.

The Number Of M&As And Their Values Declined 5% And 28%, Respectively, In 2012
Mergers and acquisitions (M&As), including asset transactions, recorded a decrease in the number of deals and deal values in 2012, due to valuation gaps between acquirers and sellers. The medical equipment industry reported 610 deals worth $50 billion in 2012, as compared to 647 deals worth $70.7 billion in 2011. Healthcare IT market managed to remain attractive to buyers in 2012. The market topped the deal activity with 151 deals worth $10.6 billion in 2012. Out of 610 deals announced in 2012, 478 were acquisitions worth $46.8 billion, 122 were asset transactions worth $3.5 billion, and 10 were mergers with undisclosed deal value. Some of the high value acquisitions in 2012 include Linde AG, a Germany-based industrial gases and engineering company, completing the acquisition of Lincare Holdings, Inc., a provider of oxygen and other respiratory therapy services, for a purchase consideration of $41.5 per share or $4,600m in cash; SXC Health Solutions Corp. (SXCI), a provider of pharmacy benefit management services, through its whollyowned subsidiary, completing the acquisition of Catalyst Health Solutions, Inc. (CHSI), a pharmacy benefit management company, for a purchase consideration of $4,400m in a cash and stock transaction and Baxter International, Inc., a global healthcare company, announcing the acquisition of Gambro AB, a medical technology company, from EQT Partners AB, a private equity firm and Investor AB, an investment company, for a total purchase consideration of SEK26.5 billion (approximately $4 billion).
According to Bhaskar Vittal, Analyst at GlobalData, “The number of M&As and also their values are expected to increase in 2013 compared to 2012 due to increasing growth prospects in the US and emerging countries such as China.

IPO Market Decreased In 2012
Equity offerings recorded a decrease in the number of deals and an increase in deal values in 2012. The industry recorded 289 deals worth $8 billion in 2012, as compared to 304 deals worth $6.4 billion in 2011. Deals in the IPO market decreased considerably in 2012. The market recorded 19 deals worth $779.8m in 2012, as compared to 29 deals worth $1.6 billion in 2011. Majority of the companies in the in vitro diagnostics business were keen to come out with their IPOs in 2012. Five in vitro diagnostics companies have announced their IPOs in 2012. Besides, the industry recorded 96 secondary offerings worth $4.7 billion and 174 deals worth $2.5 billion in 2012. In 2012, the industry recorded 107 deals worth $46.8 billion in 2012, as compared to 110 deals worth $39.7 billion in 2011. Of the 107 debt offerings reported in 2012, 36 were public debt offerings worth $18.7 billion and 71 private debt placement deals worth $28.1 billion.

Venture Capital Investments Declined In 2012
The venture capital (VC) market recorded a decline in the value of deals in 2012. The decline in venture capital investments resulted from drop in venture fundraising and less capital available for new investments. The medical equipment industry recorded deals worth $6 billion in 2012, as compared to $7 billion in 2011. However, the number of deals increased marginally to 966 in 2012 from 965 in 2011. In 2012, growth capital/expansion stage companies managed to attract much investment. The companies in growth capital/expansion stage received approximately $2 billion investments in 2012. Domain Associates, a venture capital firm with $2.4 billion assets under management, topped the list of venture financing firms by participating in 14 deals worth $345.8m in last one year. Private equity (PE) market reported an increase in the number of deals and a decrease in deal values with 88 deals worth $7.6 billion in 2012, as compared to 71 deals worth $18.8 billion in 2011. According to Bhaskar Vittal, “Number of PE/VC investments and also their value are expected to increase in 2013 compared to 2012 as growth becomes challenging for big established companies. Growth and expansion stage companies developing innovative technologies and solutions catering to the growing patient population will inevitably attract PE/VC firms attention and investments.”

North America Reported A Decline In Deal Activity In 2012
North America reported an increase in the number of deals and a decrease in deal values in 2012. The region recorded 2,209 deals worth $83.3 billion in 2012, as compared to 2,196 deals worth $88 billion in 2011, with uncertainty in the global economy discouraging companies in the region from making investments.
According to Bhaskar Vittal, our Analyst , “North America is expected to continue to witness in increase in number of M&As. Also the value of M&As is expected to reverse the trend and will witness increase in deal values due to improving growth prospects in the US and organic growth becoming a challenge to big companies.”
Europe recorded a decrease in the number of deals and deal values in 2012. The region reported 587 deals worth $24.9 billion in 2012, as compared to 666 deals worth $50.1 billion in 2011, reflecting a decrease of 12% and 50%, respectively. The Asia-Pacific region recorded a decrease in the number of deals and an increase in deal values in 2012. The region reported 353 deals worth $11.6 billion in 2012, as compared to 381 deals worth $4.9 billion in 2011